@entity1320 and XXXX recurrence: A prospective matched cohort study of inflammatory and angiogenic responses as mechanisms involved in this association.

@entity1 @entity650 @entity32 @entity834 @entity7 @entity6177 @entity281 @entity14 @entity1320
BACKGROUND: @entity834 is associated with higher rates of recurrence after surgery for @entity14 . However, the mechanisms responsible are unknown. The aim was to investigate the inflammatory and angiogenic responses in @entity1 undergoing surgery for @entity14 who had @entity1320 , and to compare the results with @entity1 without complications. METHODS: Consecutive @entity1 undergoing surgery for @entity14 with curative intent were included. @entity1 who had an @entity834 or @entity6177 were included in the @entity281 group and matched with @entity1 who had an uncomplicated postoperative course. @entity650 and @entity7 were measured in serum and peritoneal fluid. RESULTS: Serum concentration of @entity650 was higher in the @entity281 group (n  =  30) compared with the control group (n  =  30) on day 4 ( @entity281 : 42.3 [27.6-1473.2] versus control: 0.6 [0.6-17.1]  pg/ml; p  =  0.008). @entity650 in peritoneal fluid was higher in the @entity281 group at 48  h and day 4 ( @entity281 : 1000.2 [995.4-1574.0] versus control: 90.3 [35.2.6-106.1]  pg/ml; p  =  0.001). Serum @entity7 was higher in the @entity281 group on day 4 ( @entity281 : 1128.6 [427.3-10000.0] versus control: 438.3 [214.1-677.6]  pg/ml; p  =  0.001). Peritoneal @entity7 concentration was higher in the @entity281 group at 48  h and day 4 ( @entity281 : 10000.0 [2563.0-10000.0] versus control: 477.8 [313.5-814.4]  pg/ml; p  =  0.001). Two-year recurrence rate was higher in @entity1 with @entity281 ( @entity281 : 30% versus control: 4%; p  =  0.001). CONCLUSIONS: @entity1320 increases @entity650 and @entity7 after surgery for @entity14 . Amplification of @entity32 and angiogenesis might be one of the mechanisms responsible for the higher recurrence rate observed in @entity1 with @entity834 or @entity6177 .
